JP5795256B2 - Methods for in vitro diagnosis of stroke - Google Patents

Description

The present invention relates to methods and kits for in vitro diagnosis of stroke.

BACKGROUND OF THE INVENTION Stroke is one of the leading causes of death and pathology in an estimated 700,000 patients, also known as cerebrovascular disorder (CVA), diagnosed every year. Stroke is currently the third leading cause of death in the United States.

  The term “stroke” encompasses the two widely different clinical settings that are most important to distinguish. Ischemic stroke is therefore usually caused by vascular blockage and the best treatment is with thrombolytic agents such as t-PA within 3 hours of the onset of symptoms. In contrast, a hemorrhagic stroke is caused by bleeding into the brain, which prohibits any treatment with anticoagulants because it can be fatal.

  Transient ischemic attacks (TIAs, often colloquially also referred to as “mini-strokes”) are caused by changes in blood supply to certain areas of the brain, resulting in less than 24 hours by definition Results in short neurological dysfunction that lasts for a period of time; if symptoms persist, it is classified as a stroke (see, eg, Transient Ischemic Attacks: Stroke (CVA): Merck Manual Home Edition). Patients diagnosed with TIA are sometimes said to have been warned of an approaching stroke. If the duration of a vascular supply disorder lasts more than a few minutes, the nerve cells in that area of the brain die and cause permanent neuropathy. One third of people with TIA later cause recurrent TIA, and one third causes stroke due to permanent neuronal loss (Transient ischemic attack Mount Sinai Hospital, New York). Thus, identification of TIA is beneficial in that these patients are at increased risk of stroke in the future.

  The diagnosis of stroke in patients with symptoms of stroke, such as sudden numbness or blindness, confusion, severe headache, obscure language, and local paralysis, and the distinction between ischemic and hemorrhagic stroke are currently However, it relies essentially on computed tomography (CT). CT, however, is not entirely satisfactory because it has an estimated sensitivity of less than 26% in diagnosing acute stroke (Chalela et al. (2007) Lancet 369: 293-298) It is linked to a very poor performance in detecting ischemic stroke with a sensitivity of less than 33% (Reynolds et al. (2003) Clin. Chem. 49: 1733-1739). Magnetic resonance imaging (MRI) has been shown to be superior to CT in diagnosing acute strokes, especially ischemic strokes (84% sensitivity, Chahale et al. (2007) Lancet 369: 293- 298). However, MRI scanners are expensive equipment and are not always available in the emergency room.

  Thus, there remains a need for methods for diagnosing stroke and TIA, particularly alternative or complementary to CT.

  In this regard, biochemical markers have been proposed as an aid in detecting stroke, particularly in view of early detection of ischemic stroke.

  S-100b (a marker of astrocyte activation) and neuron specific enolase (NSE) are among such markers that are best characterized (Jauch et al. (2006) Stroke 37: 2508-2513). Heart-type fatty acid binding protein (H-FABP) is also considered as a promising marker (Lescuyer et al. (2005) Mol. Diagn. 9: 1-7). However, the discrimination capabilities provided by these markers do not appear to be sufficient for clinical value individually.

  Thus, such as S-100b, B-type neurotrophic growth factor (BNGF), von Willebrand factor (vWF), matrix metalloproteinase-9 (MMP-9) and monocyte chemotactic protein-1 (MCP-1) It has been proposed to use a panel that combines several markers for diagnosing ischemic strokes (Reynolds et al. (2003) Clin. Chem. 49: 1733-1739). In fact, this panel was shown to give a sensitivity of 92% with a specificity of 93% for ischemic stroke samples within 6 hours of the onset of symptoms. However, within 3 hours of onset, the sensitivity is only 87%, which may be due to the too low individual sensitivity / specificity of the marker.

  Therefore, it can be used to test single markers or improve multiple marker panels by increasing the sensitivity / specificity or allowing to reduce the number of markers whose levels must be measured in the panel As such, there remains a need for alternative markers that provide sufficient individual sensitivity / specificity ratios.

  ProBNP (1-108), which is a precursor protein consisting of 108 amino acids, is cleaved in vivo to give (i) a brain natriuretic peptide consisting of 32 C-terminal amino acids of proBNP (1-108) ( And (ii) NT-proBNP (1-76) consisting of the 76 N-terminal amino acids of proBNP (1-108) (Giuliani et al. (2006) ) Clinical Chemistry 52: 1054-61). Biologically, BNP is a blood pressure regulator that is released primarily from the left ventricle in response to volume expansion and pressure overload. ProBNP (1-108) has been shown to circulate in patients with severe heart failure (Hammerer-Lercher et al. (2008) Clinical Chemistry 54: 5).

  This invention is unexpected by the inventors that proBNP (1-108) alone had a high discriminatory ability in stroke detection (eg 95% sensitivity and 95% specificity as measured in plasma samples) It arises from knowledge.

Accordingly, the present invention is a method for in vitro diagnosis of stroke and transient ischemic stroke (TIA) in an individual comprising:
(A) measuring the level of proBNP (1-108) or a fragment of proBNP (1-108) comprising a RAPRSP sequence (SEQ ID NO: 1) in a biological sample of an individual;
(B) comparing the measured level with a cutoff value;
(C) then determining whether a stroke or TIA has occurred in the individual.

In certain embodiments of the method defined above, the present invention more particularly,
(A ′) measuring the level of proBNP (1-108) or a fragment of proBNP (1-108) comprising a RAPRSP sequence (SEQ ID NO: 1) in a biological sample of an individual;
(B ′) measuring the level of at least one additional stroke marker in the biological sample of the individual;
(C ′) comparing the level of the proBNP (1-108) or proBNP (1-108) fragment and the level of at least one additional stroke marker to one or several cutoff values;
(D ′) and then determining whether a stroke or TIA has occurred in the individual.

  In another embodiment of the invention, the method as defined above further comprises measuring the level of at least one cardiovascular disease marker.

The invention further provides:
-At least one antibody suitable for detecting a fragment of proBNP (1-108) comprising proBNP (1-108) or a RAPRSP sequence (SEQ ID NO: 1); and-proBNP (1-108) or It also relates to a kit for diagnosing stroke comprising at least one calibrator comprising a fragment of proBNP (1-108) comprising a RAPRSP sequence (SEQ ID NO: 1), preferably at a concentration of 1-1000 pg / ml.

  The invention further relates to the use of a proBNP (1-108) or fragment of proBNP (1-108) comprising the RAPRSP sequence (SEQ ID NO: 1) for in vitro diagnosis of stroke or TIA.

The distribution of H-FABP concentration (vertical axis: ng / ml) in the stroke population and the control population is represented. 2 represents the distribution of proBNP (1-108) concentration (vertical axis: pg / ml) in the stroke population and the control population. 1 represents the distribution of proBNP (1-108) concentration (vertical axis: pg / ml) in the stroke population, TIA population and control population. 2 represents the distribution of proBNP (1-108) concentration (vertical axis: pg / ml) in the stroke population and the control population. It represents the distribution of S-100b concentration (vertical axis: ng / ml) in the stroke population and the control population. The distribution of NSE concentration (vertical axis: ng / ml) in the stroke population and the control population is represented.

DETAILED DESCRIPTION OF THE INVENTION As intended herein, establishing “diagnose” or “diagnosis” relates to determining whether a stroke has occurred in an individual.

  As intended herein, “stroke” refers to all cerebrovascular disorders. In particular, the term “stroke” encompasses acute and chronic stroke, as well as ischemic and hemorrhagic stroke.

  Ischemic stroke is characterized by partial or total occlusion of cerebral blood vessels that may lead to infarction and necrosis of brain cells supplied by cerebral blood vessels. In a transient ischemic attack (TIA), the occlusion causes dysfunction that does not persist beyond 24 hours and stops spontaneously.

Hemorrhagic stroke is generally characterized by intracerebral hemorrhage from cerebrovascular rupture.
Preferably, according to this invention, the stroke is selected from the group consisting of ischemic stroke and hemorrhagic stroke. More preferably, the stroke contemplated herein is an acute ischemic stroke.

  Advantageously, the method of the present invention allows for early stroke diagnosis. Early stroke diagnosis is particularly important in the case of ischemic stroke because treating occluded blood vessels within 3 hours of the onset of stroke symptoms will prevent most irreversible brain damage This is because it is usually estimated. Accordingly, step (a) as defined above is preferably performed within 6 hours, more preferably within 3 hours, most preferably within 2 hours after the onset of at least one symptom indicative of stroke in the individual. .

  Symptoms indicative of stroke are well known to those skilled in the art and include, among others, sudden numbness or blindness, confusion, severe headaches, obscure language and localized paralysis.

The individual is preferably a human.
“ProBNP (1-108)” relates to the precursors BNP (32) and NT-proBNP (1-76). As intended herein, “proBNP (1-108)” includes all its natural variants. Illustratively, proBNP (1-108) is represented by SEQ ID NO: 4.

  In vivo, proBNP (1-108) is often partially cleaved, especially by deleting one or more amino acids at the N-terminus or optionally at the C-terminus, for example by circulating a protease. Forms a “proBNP (1-108) fragment”. An example of such a proBNP (1-108) fragment, proBNP (3-108) produced by cleavage with dipeptidase, is found in Lam et al. (2007) J. Am. Coll. Cardiol. 49: 1193-1202 Have been described. It is believed that not only proBNP (1-108) is valuable but also the various natural fragments thereof. Thus, the present invention not only measures the level of proBNP (1-108), but also depends on the level of proBNP (1-108) fragment.

  The expressions “proBNP (1-108)” and “fragments of proBNP (1-108)” also include any polypeptide that has undergone at least one post-translational modification, such as phosphorylation, glycosylation, and the like. For example, Schellenberger et al. (2006) Arch. Biochem. Biophys. 51: 160-6 showed that proBNP (1-108) is a glycoprotein that forms O-glycans in whole or in part.

  As intended herein, the fragment of proBNP (1-108) contains the RAPRSP sequence (SEQ ID NO: 1). This RAPRSP sequence contains the site of proBNP (1-108) which is cleaved in vivo to produce NT-proBNP (1-76) and BNP (32). Thus, since RAPRSP is unique to proBNP (1-108) and cannot be found in BNP (32) and NT-proBNP (1-76), they are therefore proBNP (1 -108) is excluded from the definition of fragments.

  It is further preferred that the fragment of proBNP (1-108) according to the invention comprises the FGRKMDR sequence (SEQ ID NO: 2). This sequence is contained in the BNP (32) portion of proBNP (1-108). Even more preferably, the fragment of proBNP (1-108) comprises the entire sequence of BNP (32) (SEQ ID NO: 3).

  The expression "further stroke marker" relates to any biochemical marker other than the proBNP (1-108) or proBNP (1-108) fragments defined above, the levels of which are defined above. Indicates a stroke or TIA.

  The expression “marker for heart disease” relates to any marker useful for detecting or diagnosing cardiovascular disease. Such markers are well known to those skilled in the art. Preferably, the marker for cardiovascular disease is selected from the group consisting of C-reactive protein (CRP) and cardiac troponin I (cTnI). Measuring the level of a marker of cardiovascular disease may be advantageous in the method of the present invention because it eliminates cardiovascular disease as a cause for variations in proBNP (1-108) levels. It is because it makes possible.

  Preferably, measuring or determining the level of proBNP (1-108), a fragment of proBNP (1-108), at least one additional stroke marker, or at least one cardiovascular disease marker is determined using an immunoassay. Is done.

  As intended herein, an “immunoassay” refers to the level of proBNP (1-108), a fragment of proBNP (1-108), at least one additional stroke marker, or at least one marker of cardiovascular disease. It relates to any method of determination using at least one compound (or ligand) that specifically binds. The compound (or ligand) that specifically binds to it can be of any kind, but is preferably an antibody, aptamer or peptide obtained by phage display. Immunoassay methods are well known to those skilled in the art and may be performed in a variety of formats well known to those skilled in the art, for example, solid phase or soaking, one or two steps, sandwich methods or competitive methods.

  Preferably, a sandwich method in the solid phase between two ligands, one being the capture ligand and the other being the detection ligand, will be used. This type of immunoassay is particularly well known to those skilled in the art. For example, a paper by Seferian et al. (2007) Clin. Chem. 53: 866-873 uses a pair of antibodies (an antibody immobilized on a solid phase and an antibody labeled with detection) each time using a BNP ( 32) and an example of a sandwich immunoassay (or immunometric assay at two sites) for assaying proBNP (1-108).

  The presence of the antigen in the biological sample is revealed by a detection means, in particular a “detection ligand”. The detection ligand is labeled and can bind to the captured antigen by recognizing a site of an epitope different from that recognized by the capture ligand.

  The expression “labeled” means direct labeling and indirect labeling (eg, by other ligands that are themselves labeled or, but not exclusively, labeled avidin-biotin pairs, etc. , Using labeled "affinity pair" reagents).

  In the case of the sandwich method, the capture ligand is preferably selected such that it specifically recognizes an epitope in the patient's natural antigen, while the detection ligand is preferably in the patient's natural antigen. It is selected in such a manner as to specifically recognize other epitopes.

  Preferably, the capture ligand is immobilized in the solid phase. As a non-limiting example of a solid phase, microplates can be used, in particular polystyrene microplates such as those sold by Nunc, Denmark. Solid particles or beads, paramagnetic beads, such as those manufactured by Dynal, Merck-Eurolab (France) and Polymer Laboratories (under the Estapor ™ trademark), or polystyrene or polypropylene test tubes, glass, plastic or silicon tips, etc. Even may be used.

  An ELISA assay, radioimmunoassay, or any other detection method may be used to reveal the presence of the antigen-antibody complex formed. In this way, different types of ligands, in particular antibodies, can be labeled (radioactive, enzymatic, fluorescent etc.).

  In addition, detection is based on mass accumulation based methods such as surface plasmon resonance (SPR), piezoelectric detection, and further studies of ligand-antigen type interactions in the absence of mass spectrometry or a second labeled ligand. May be performed by any other method defined as enabling.

  The term “specific” means that when it refers to ligand recognition or ligand binding to a target, the interaction between the ligand and the target is substantially equivalent to other targets whose ligand is structurally similar to that target. It means to occur without interaction.

“Antibody” as intended herein relates to an antibody belonging to any species, such as a human, mouse, rat, rabbit, goat or camelid species. The antibody may further be a chimeric antibody, ie an antibody comprising portions derived from different species. Preferred chimeric antibodies are so-called “human-adapted” antibodies, where the constant regions (C _H and C _L ) are of human origin and the variable regions (V _H and V _L ) are in other species such as mice, for example. is there. The antibodies of this invention can be produced by animal sensitization, or any method known to those skilled in the art, such as, for example, recombinant or synthetic methods. Moreover, “antibodies” according to the invention further include antibody fragments comprising at least one of the paratopes of said antibody, such as Fab, F (ab ′) ₂ , scFv fragments, camelid single chain antibodies, and the like. To do. The antibodies of this invention can be polyclonal antibodies, particularly monospecific polyclonal antibodies, or monoclonal antibodies.

  “Aptamers” are well known to those skilled in the art. Aptamers are nucleotide compounds, particularly ribonucleotides or dezoxyribonucleotides, or natural peptides that can specifically bind to a target, particularly a protein target. Natural nucleotide aptamers and their production are described in particular by Ellington et al. (1990) Nature 346: 818-22 and Bock et al. (1992) Nature 355: 564-6.

  “Phage display” is a technique for selecting polypeptide ligands that are expressed on the capsid of a bacteriophage and encoded by a nucleic acid sequence that is inserted into a capsid-encoding gene. This method is well known to those skilled in the art and is described in particular by Scott and Smith (1990) Science 249: 386-390, and Marks et al. (1991) J. Mol. Biol. 222: 581-597. Yes. Preferably, the polypeptide obtainable by phage display is a scFv type polypeptide (single chain variable fragment). This technique is described in particular in Winter et al. (1994) Annu. Rev. Immunol. 12: 433-455.

  Preferably, the immunoassay defined above comprises an antibody that targets an epitope comprising the RAPRSP sequence (SEQ ID NO: 1). More preferably, the antibody is a CNCM (Collection Nationale de Cultures de Microorganismes, Institut Pasteur, 25, rue du Docteur Roux, 75 724 Paris Cedex, April 29, 2005, under the Budapest Treaty, under registration number I-3073. 15, secreted by the hybridoma deposited in France). Such antibodies are described in particular in international publication WO 2004/014952. This antibody is advantageous because it specifically excludes BNP (32), NT-proBNP (1-76) and their respective fragments, proBNP (1-108) and proBNP (1-108) according to the invention. ) To allow specific detection of all fragments, thereby ensuring full diagnostic benefit of proBNP (1-108) and its various fragments.

  More preferably, the immunoassay comprises an antibody that targets an epitope comprising the FGRKMDR sequence. More preferably, this antibody is produced by CNCM (Collection Nationale de Cultures) by Bio-Rad (3 boulevard Raymond Poincare, 92430 Marnes la Coquette, France) under registration number I-3746 on April 13, 2007 under the Budapest Treaty. de Microorganismes, Institut Pasteur, 25, rue du Docteur Roux, 75 724 Paris Cedex 15, France). Such antibodies are described in particular in the international application PCT / EP2008 / 060188.

  Advantageously, an antibody that targets an epitope comprising a RAPRSP sequence (SEQ ID NO: 1) and an antibody that targets an epitope comprising an FGRKMDR sequence are combined in the same immunoassay, thereby producing a proBNP according to the invention ( Allows the specific detection of fragments of 1-108) and proBNP (1-108).

  Preferably, when referring to proBNP (1-108) or a fragment of proBNP (1-108), the cut-off value defined above is proBNP according to the invention in a biological sample obtained from a population of apparently healthy individuals It is at least the median level of a fragment of (1-108) or proBNP (1-108). More preferably, the cut-off value as defined above is at least 75th of the level of proBNP (1-108) or proBNP (1-108) fragments according to this invention obtained from a population of apparently healthy individuals. A value corresponding to the percentile, the 95th percentile, or the 99th percentile. Most preferably, this cutoff value is at least 0 pg / ml, 1 pg / ml, 2 pg / ml, 3 pg / ml, 5 pg / ml, 10 pg / ml, 50 pg / ml, or 100 pg / ml. If the cut-off value is at least 0 pg / ml, this means that steps a) and b), or a ′) or c ′) defined above in the method of the invention are simply proBNP as defined above. Means to determine whether a fragment of (1-108) or proBNP (1-108) is present in an individual's biological sample.

  Similarly, for at least a further stroke marker, the cutoff value defined above is preferably at least at the median level of the at least one further stroke marker in a biological sample obtained from a population of clearly healthy individuals. is there.

  Determining the cut-off value according to the present invention is well within the ordinary skill of one skilled in the art. In particular, care should be taken when measuring the level of proBNP (1-108), a fragment of proBNP (1-108) according to the invention, or at least one further stroke marker in a biological sample of the same nature . As intended herein, a “popularly healthy population of individuals” preferably relates to individuals who do not exhibit any symptoms indicative of stroke as defined above.

  When comparing the level of proBNP (1-108), a fragment of proBNP (1-108), and at least one additional stroke marker with one or several cut-off values, it is possible that one proBNP (1-108) Or the level of the fragment of proBNP (1-108) and the level of the other at least one further stroke marker can each be compared to a respective cut-off value, or they both have a single cut-off value It means that you can compare.

  Preferably, the level of at least a further stroke marker or at least one cardiovascular disease marker is measured in the same biological sample as the sample from which the level of proBNP (1-108) or proBNP (1-108) fragment is measured. .

  As intended herein, the expression “biological sample” refers to both a sample as taken, as well as a sample that has undergone various treatments in order to be suitable for use in the processes and methods according to the present invention. including. The biological sample according to the invention can be of any kind, but preferably the biological sample is selected from the group consisting of blood samples, serum samples, plasma samples, cerebrospinal fluid samples, urine samples and saliva samples. It is preferable.

  Example

1. Method a. Samples ProBNP (1-108) and H-FABP levels were determined from 70 serum samples (15 hemorrhagic stroke samples (HM) and 55 ischemic strokes) obtained from individuals who had a stroke within 3 hours after onset. Sample (IM)) as well as 148 control serum samples from clearly healthy individuals.

b. Biomarker measurements ProBNP (1-108) levels were measured using the BioPlex ™ 2200 proBNP (1-108) assay (Bio-Rad).

  BioPlex ™ 2200 combines multiple magnetic beads and flow cytometry technology to provide multi-analyte detection on a fully automated random access platform. Magnetic particles (8 μm diameter, carboxyl modified surface) are stained with two fluorophores (classifying dyes, CL1 and CL2) that emit at distinct wavelengths and absorb significantly at 635 nm. The reporter fluorophore, β-phycoerythrin (PE), was chosen for its high molar extinction coefficient, quantum yield, photobleaching resistance, lack of self-quenching, and stability. The detector simultaneously measures three wavelengths: two classification dyes and a reporter dye.

  The BioPlex ™ 2200 proBNP (1-108) assay is a two-step sandwich fluorescent immunoassay. In the first step, the BioPlex ™ 2200 system is magnetically coated with an anti-proBNP (1-108) monoclonal antibody secreted by a 50 μL patient sample, a hybridoma deposited with the CNCM under accession number I-3073. Combine stained beads and assay buffer in a reaction vessel. Then, after an 11 minute incubation and wash cycle, an anti-human BNP monoclonal antibody secreted by the hybridoma deposited at CNCM with accession number I-3746 conjugated to phycoerythrin (PE) was added and incubated for 2 minutes Was done. After removal of excess conjugate, the bead mixture is passed through a detector, thereby identifying the amount of antigen captured on the beads by the fluorescence of the stained beads and PE. After calibration with a set of six separate calibrators, the three levels of quality control and patient sample results are expressed in pg / mL.

  Two quality control beads are also tested on each sample to improve the integrity of the overall system.

  H-FABP levels were measured using a human H-FABP ELISA kit from Hycult biotechnology according to the manufacturer's instructions.

c. Statistical analysis The distribution of biomarkers according to the patient's condition was represented by a boxplot representation, because it represented a group of numerical data with a five-number summary (minimum observation, lower quartile ( This is because it is a convenient method of graphical representation via Q1), median (Q2), upper quartile (Q3), and maximum observed value).

  Data has been normalized to allow statistical analysis using the Box-Cox method, following a Gaussian distribution (Box, GEP and Cox, DR (1964) An analysis of transformations. JRSS B 26, 211-246).

  The Wilcoxon Rank Sum for differential analysis between control and stroke samples is the following statistical test: nonparametric (does not require statistical distribution assumptions and can be an alternative to Student's t-test) Test (Wilcoxon, F. (1945). Individual comparisons by ranking methods. Biometrics, 1, 80-83), and possibly a student's t intended for use with two samples with unequal variances The test was performed using Welch's assay, which is a match for the assay. Analysis is further based on the Benjamini / Hochber method (Benjamini and Y. Hochberg (1995). Controlling the False Discovery Rate: a practical and powerful approach to multiple testing. JR Statist. Soc. B. Vol. 57: 289-300) An adjusted (corrected) version of these tests was also performed.

  The diagnostic performance of the marker was characterized by two indicators: sensitivity (ability to detect disease population) and specificity (ability to detect control population). The result of the diagnostic test can be further characterized by determining the area under the curve (AUC) of the ROC (Receiver Operating Characteristic) analysis. ROC curves are graphical visualizations of the reciprocal relationship between test sensitivity (Se) and specificity (Sp) for various concentrations (MH Zweig and G. Campbell (1993). "Receiver-operating characteristic ( ROC) plots: a fundamental evaluation tool in clinical medicine ". Clinical chemistry 39 (8): 561-57).

2. Results a. Biomarker Distribution by Box Plot Representation FIGS. 1 and 2 represent the distribution of H-FABP and proBNP (1-108) concentrations in the stroke population and the control population, respectively.

  Table 1: H-FABP and proBNP (1-108) levels in the control and stroke populations

  The proBNP (1-108) marker shows a higher concentration level in the stroke sample than in the control sample. On the other hand, the measured H-FABP concentration does not show any significant difference between the stroke patient sample and the control sample.

b) Differential analysis The statistical significance of differences in H-FABP and proBNP (1-108) levels between stroke and control samples was determined:
Table 2: Differential analysis between concentrations measured from the control and stroke populations for the H-FABP marker and the proBNP (1-108) marker

The difference between concentrations between the stroke and control samples was statistically significant for both markers (proBNP (1-108) and H-FABP), but proBNP (1-108) ^Exhibit particularly interesting properties with low p-values (10 ⁻⁴ ) (Table 2).

c) ROC curve analysis Based on the Received Operating Characteristic (ROC) analysis for clinical conditions and summarized in Table 3, the area under the curve for proBNP (1-108) is 90% sensitive, 85% specific. It has succeeded in distinguishing patients diagnosed with stroke from healthy subjects. Furthermore, this discrimination ability is very high with an AUC of 0.936 and 0.935, respectively, for both ischemic and hemorrhagic stroke patients.

  Table 3: Receiving behavior characteristic analysis data for proBNP (1-108) for stroke patients compared to control subjects

  As shown in Table 4 below, the H-FABP marker has a low discrimination ability for stroke diagnosis with 57% sensitivity, 54.7% specificity.

  Table 4: Receiving behavior characteristic analysis data for H-FABP for stroke patients compared to control subjects

1. Method a. Samples proBNP (1-108) levels were determined from 23 serum samples (5 hemorrhagic stroke samples (HM) and 18 ischemic stroke samples (IM) obtained from individuals who had a stroke within 3 hours after onset. ), Measured in 7 serum samples obtained from individuals clinically diagnosed with TIA, as well as 94 control serum samples from apparently healthy individuals.

b. Marker level measurement The proBNP (1-108) level was measured as shown in Example 1.

c. Statistical analysis Box plot representation and ROC analysis of the proBNP (1-108) level distribution was performed as shown in Example 1.

2. Results a) Distribution of biomarkers by box plot representation FIG. 3 represents the distribution of proBNP (1-108) concentrations in the stroke population, the TIA population and the control population.

  Table 5: proBNP (1-108) distribution values in the control, TIA and stroke populations

  The proBNP (1-108) marker shows a higher concentration level in stroke patient samples or TIA patient samples than in control samples.

b) ROC curve analysis Based on the Received Operating Characteristic (ROC) analysis for clinical conditions and as summarized in Table 6, the area under the curve for proBNP (1-108) is 91% sensitive, 84% specific. It has succeeded in distinguishing patients diagnosed with stroke from healthy subjects.

  Table 6: Received operating characteristic analysis data for proBNP (1-108) for stroke patients compared to control subjects

  The ability of proBNP (1-108) to diagnose stroke patients, as demonstrated in Example 1, is thus confirmed in these new pathological and healthy populations.

  The discrimination ability of proBNP (1-108) was further compared with that of two prior art reference stroke markers (S-100b and NSE) in the same population.

1. Method a. Sample marker levels were measured in 41 plasma samples obtained from individuals who had a stroke within 3 hours of onset, and in control plasma samples from apparently healthy individuals.

b. Marker level measurement The proBNP (1-108) level was measured as shown in Example 1.

  NSE levels were measured using the Nexus DX ™ Neuron Specific Enolase (NSE) Test kit from Nanogen according to the manufacturer's instructions.

  S-100b levels were measured using a Nexus DX ™ S-100 ELISA Test kit from Nanogen according to the manufacturer's instructions.

c. Statistical analysis Statistical analysis was performed as shown in Example 1.

2. Results a) Distribution of biomarkers by box plot representation FIGS. 4, 5 and 6 represent the distribution of proBNP (1-108) concentration, S-100b concentration and NSE concentration in the stroke population and the control population, respectively. .

  Table 7: proBNP (1-108), S100 and NSE distribution values in the control and stroke populations

  The proBNP (1-108) and NSE markers show higher concentration levels in the stroke sample than in the control sample. The best discrimination between both populations is observed with the proBNP (1-108) marker. On the other hand, the measured S-100 concentration does not show any significant difference between the stroke patient sample and the control sample.

b) Differential analysis The statistical significance of differences in proBNP (1-108) level, NSE level and S-100 level in stroke and control samples was determined:
Table 8: Differential analysis between concentrations measured from control and stroke populations for NSE, S-100 and proBNP (1-108) markers

  NSE and proBNP (1-108) are statistically significant with very low p-values (p <0.001).

c) ROC curve analysis Based on the received operating characteristic (ROC) analysis for clinical status and summarized in Table 9, the area under the curve for proBNP (1-108) is 95% sensitivity, 95% specificity and With an AUC of 0.974, we have successfully distinguished patients diagnosed for stroke from healthy subjects.

  Table 9: Received operating characteristic analysis data for proBNP (1-108), NSE and S-100 for stroke patients compared to control subjects

  It can be seen that proBNP (1-108) exhibits a higher discrimination ability than that provided by NSE and S-100b in distinguishing stroke patients from control subjects.

  The diagnostic ability of proBNP (1-108) was further evaluated in patients with ischemic stroke using the BioPlex ™ 2200 proBNP (1-108) assay as described in Example 1.

a) Samples-Thirty-two citrated plasma samples from ischemic stroke patients received in the emergency department within 3 hours of stroke onset were examined. Stroke severity was assessed on the National Institutes of Health Stroke Scale (NIHSS).

  -42 citrated plasma samples from apparently healthy blood donors matched to gender and age with patients from the stroke population were examined.

  All citrated plasma samples were stored at -80 ° C. Prior to analysis, samples were thawed and centrifuged at 3000g for 15 minutes at 4 ° C.

b) Results The distribution of proBNP (1-108) values for the control population and the ischemic stroke population is shown in Table 10. The level of proBNP (1-108) was significantly higher in the ischemic stroke group compared to the control group (Mann-Whitney, p <0.0001). These results confirm that proBNP (1-108) is therefore a useful plasma biomarker for early diagnosis of ischemic stroke.

  Table 10: ProBNP (1-108) concentration (minimum, first quartile, median, third quartile) in citrated plasma samples of ischemic stroke and control citrated plasma samples And maximum)

Claims (15)

A method of providing data for in vitro diagnosis of stroke or transient ischemic stroke (TIA) in an individual comprising:
(A) measuring the level of proBNP (1-108) or a fragment of proBNP (1-108) comprising the RAPRSP sequence (SEQ ID NO: 1) in a biological sample of said individual;
(B) viewing including the step of comparing the cut-off value measured level,
A method wherein the level of proBNP (1-108) or a fragment of proBNP (1-108) is measured using an immunoassay comprising an antibody targeting an epitope comprising the RAPRSP sequence (SEQ ID NO: 1) .   2. The method of claim 1, wherein the fragment of proBNP (1-108) further comprises an FGRKMDR sequence (SEQ ID NO: 2).   The method according to claim 1 or 2, wherein the fragment of proBNP (1-108) comprises the sequence of BNP (32) (SEQ ID NO: 3).   4. The method according to any of claims 1 to 3, wherein the stroke is selected from the group consisting of ischemic stroke and hemorrhagic stroke.   5. The method according to any of claims 1 to 4, wherein step (a) is performed within 6 hours after the onset of at least one symptom indicative of stroke in the individual. The antibody, registered under April 29, 2005 of the Budapest Treaty No. I-3073 at CNCM (Paris, France) is secreted by the hybridoma deposited with the method of claim 1. 7. The method of claim 1 or 6 , wherein the immunoassay comprises an antibody that targets an epitope comprising the FGRKMDR sequence (SEQ ID NO: 2). The antibody, under the Budapest Treaty April 13, 2007 to the registration number I-3746 at CNCM (Paris, France) is secreted by the hybridoma deposited with the method of claim 7. The cut-off value is at least 1 pg / ml, A method according to any one of claims 1 to 8. (A ′) measuring the level of proBNP (1-108) or a fragment of proBNP (1-108) comprising a RAPRSP sequence (SEQ ID NO: 1) in a biological sample of an individual;
(B ′) measuring the level of at least one additional stroke marker in the biological sample of the individual;
(C ′) comparing the level of proBNP (1-108) or a fragment of proBNP (1-108) and the level of said at least one additional stroke marker with one or several cutoff values; the method of any of claims 1-9. 11. The method of claim 10 , wherein the level of the at least further stroke marker is measured in the same sample as the biological sample in which the level of proBNP (1-108) or proBNP (1-108) fragment is measured. The biological sample is a blood sample, a serum sample, a plasma sample, cerebrospinal fluid sample is selected from the group consisting of a urine sample and a saliva sample, A method according to any one of claims 1 to 11. Further comprising measuring the level of marker of at least one cardiovascular disease, the method according to any one of claims 1 to 12. 14. The method of claim 13 , wherein the at least one cardiovascular disease marker is selected from the group consisting of CRP and cTnI.   Use of proBNP (1-108) or a fragment of proBNP (1-108) containing the RAPRSP sequence (SEQ ID NO: 1) for in vitro diagnosis of stroke or TIA.